Caribou Biosciences (CRBU) Leases (2022 - 2026)

Caribou Biosciences (CRBU) has 5 years of Leases data on file, last reported at $17.4 million in Q1 2026.

• Quarterly Leases fell 11.09% year-over-year to $17.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $17.4 million (down 11.09% YoY) and the FY2025 annual result came in at $17.7 million, down 11.69% from the prior year.
• Leases fell to $17.4 million in Q1 2026 per CRBU's latest filing, from $17.7 million in the prior quarter.
• Across five years, Leases topped out at $25.7 million in Q1 2022 and bottomed at $16.0 million in Q3 2025.
• The 5-year median for Leases is $21.7 million (2024), against an average of $21.3 million.
• The widest annual swing landed in 2023, when Leases decreased 7.9%; it then retreated 22.11% in 2025.
• Tracing CRBU's Leases over 5 years: stood at $24.2 million in 2022, then dropped by 8.45% to $22.2 million in 2023, then fell by 9.8% to $20.0 million in 2024, then fell by 11.69% to $17.7 million in 2025, then decreased by 1.78% to $17.4 million in 2026.
• Per Business Quant, the three latest CRBU Leases figures stand at $17.4 million (Q1 2026), $17.7 million (Q4 2025), and $16.0 million (Q3 2025).

Peer Comparison